Sinocelltech Group Past Earnings Performance
Past criteria checks 0/6
Sinocelltech Group has been growing earnings at an average annual rate of 19.6%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 91.1% per year.
Key information
19.6%
Earnings growth rate
22.7%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 91.1% |
| Return on equity | n/a |
| Net Margin | -7.8% |
| Next Earnings Update | 22 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Sinocelltech Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,171 | -169 | 647 | 1,129 |
| 31 Dec 23 | 1,887 | -396 | 585 | 1,139 |
| 30 Sep 23 | 1,752 | -336 | 534 | 1,083 |
| 30 Jun 23 | 1,455 | -407 | 482 | 1,014 |
| 31 Mar 23 | 1,196 | -529 | 435 | 946 |
| 31 Dec 22 | 1,023 | -519 | 398 | 882 |
| 30 Sep 22 | 775 | -609 | 357 | 819 |
| 30 Jun 22 | 510 | -680 | 314 | 746 |
| 31 Mar 22 | 290 | -818 | 274 | 755 |
| 31 Dec 21 | 134 | -867 | 248 | 726 |
| 30 Sep 21 | 10 | -859 | 201 | 667 |
| 30 Jun 21 | 0 | -809 | 175 | 661 |
| 31 Mar 21 | 0 | -755 | 153 | 634 |
| 31 Dec 20 | 0 | -713 | 141 | 608 |
| 30 Sep 20 | 0 | -709 | 132 | 608 |
| 30 Jun 20 | 1 | -707 | 139 | 581 |
| 31 Mar 20 | 2 | -837 | 332 | 640 |
| 31 Dec 19 | 3 | -795 | 307 | 511 |
| 31 Dec 18 | 3 | -453 | 72 | 426 |
| 31 Dec 17 | 6 | -141 | 23 | 182 |
Quality Earnings: 688520 is currently unprofitable.
Growing Profit Margin: 688520 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688520 is unprofitable, but has reduced losses over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare 688520's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688520 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 688520's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.